Vivo Capital Surplus Fund VIII, L.P.

CIK 1628048 · last filed 2024-04-03

Vivo Capital Surplus Fund VIII, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider sold $14.0M of TERN on Apr 3, 2024. Across all open-market trades the lifetime net is +$44.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $25.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$25.45M

Companies

3

Total Filings

9

Lifetime Open-Market Net

$44.19M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Terns Pharmaceuticals, Inc. (TERN) Delisted	10%+ Owner	275,772	$52.95	$14.60M	-$3.18M	2	2024-04-03
ALGS	10%+ Owner	96,373	$4.23	$407.7K	$24.75M	1	2020-10-20
CRNX	10%+ Owner	298,625	$83.85	$25.04M	$22.62M	4	2020-04-17

Recent Filings

9 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2024-04-03	Terns Pharmaceuticals, Inc. (TERN) Delisted	Sell (S)	−2,103,315	-$13.98M	EDGAR
2024-04-03	Terns Pharmaceuticals, Inc. (TERN) Delisted	Notice (144)	−5,443	-$32.7K	EDGAR
2024-04-01	Terns Pharmaceuticals, Inc. (TERN) Delisted	Notice (144)	−8,832	-$66.8K	EDGAR
2022-09-08	Terns Pharmaceuticals, Inc. (TERN) Delisted	Buy (P)	+3,000,000	$10.80M	EDGAR
2020-10-20	ALGS	Mixed	+10,641,090	$24.75M	EDGAR
2020-04-17	CRNX	Sell (S)	−991,794	-$15.32M	EDGAR
2020-03-11	CRNX	Sell (S)	−2,640	-$51.5K	EDGAR
2020-02-11	CRNX	Sell (S)	−67,300	-$1.46M	EDGAR
2018-07-20	CRNX	Mixed	+22,424,748	$39.45M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.